Reckitt Benckiser Plc (RBGLY)
$19.21 0.01 (0.05%)
15:59 EDT RBGLY Stock Quote Delayed 30 Minutes
Previous Close $19.21
Market Cap 67.86B
PE Ratio -
Volume (Avg. Vol.) 156,600
Day's Range 19.11 - 19.35
52-Week Range 12.76 - 21.00
Dividend & Yield 0.43 (2.25%)
RBGLY Stock Predictions, Articles, and Reckitt Benckiser Plc News
- From InvestorPlace
- From the Web
Reports show that not many companies are interested in Pfizer's (PFE) consumer health arm. Here's what they're balking at and what it means for PFE stock owners.
McCormick (MKC) has announced that it will be acquiring the food division of Reckitt Benckiser (RBGLY) for $4.2 billion.
Activist investor Nelson Peltz is circling Procter & Gamble (PG) with growth ideas. But they could bankrupt PG stock in a recession.
Mead Johnson Nutrition CO (MJN) stock was up on Friday following news that Reckitt Benckiser Group Plc-ADR (RBGLY) will acquire it.
Aytu BioScience to Report Fourth Quarter FY 2020 Results and Business Update on Thursday, September 24, 2020
Live Conference Call and Webcast at 4:30 ET ENGLEWOOD, CO / ACCESSWIRE / September 16, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the fiscal fourth quarter ended June 30, 2020 on September 24, 2020, at 4:30 p.m. ET. The Company
From Seeking Alpha
Aytu BioScience Announces Global Agreement to Distribute Pinnacle IVD Corporation's 15-Minute COVID-19 Antigen Test
Pinnacle Plans to Scale U.S. Manufacturing Capacity to 25 Million Tests Per Month Cost-Effective 15-Minute Rapid Antigen Test Demonstrates 100% Specificity for COVID-19 Detection When Compared with RT-PCR ENGLEWOOD, CO / ACCESSWIRE / September 8, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs